Skip to main content

Table 5 Correlation between disease characteristics and CT-based therapeutic response in the study population

From: Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma

 

Objective response by RECIST

Test value*

P value

Sig.

CMR

PMR

SMD

PMD

No. =  8

No. = 18

No. = 3

No. = 4

Pathology

NHL

3 (37.5%)

9 (50.0%)

0 (0.0%)

3(75.0%)

5.435

0.489

NS

HL

5 (62.5%)

8 (44.4%)

3 (100.0%)

1 (25.0%)

GALT

0 (0.0%)

1 (5.6%)

0 (0.0%)

0 (0.0%)

Location

NA

1 (12.5%)

2 (11.1%)

0 (0.0%)

1 (25.0%)

10.530

0.104

NS

Supra

6 (75.0%)

5 (27.8%)

3 (100.0%)

1 (25.0%)

Supra & infra

1 (12.5%)

11 (61.1%)

0 (0.0%)

2 (50.0%)

Stage

I

1 (12.5%)

1 (5.6%)

0 (0.0%)

0 (0.0%)

26.203

0.095

NS

IE

1 (12.5%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

II

4 (50.0%)

4 (22.2%)

3 (100.0%)

0 (0.0%)

IIE

1 (12.5%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

III

0 (0.0%)

3 (16.7%)

0 (0.0%)

2 (50.0%)

IIIS

1 (12.5%)

6 (33.3%)

0 (0.0%)

0 (0.0%)

IV

0 (0.0%)

4 (22.2%)

0 (0.0%)

2 (50.0%)

New lesion

Absent

8 (100.0%)

18 (100%)

3 (100.0%)

0 (0.0%)

33.000

0.000

HS

Present

0 (0.0%)

0 (0.0%)

0 (0.0%)

4 (100.0%)

  1. P value > 0.05 Non significant (NS), P value < 0.05 Significant (S), P value < 0.01 Highly significant (HS)
  2. *Chi-square test